Symbols / TERN Stock $52.95 -0.03% Terns Pharmaceuticals, Inc.
TERN (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Ratings
Current target
$52.95
Low
$53.00
High
$53.00
Mean
$53.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-27 | down | Oppenheimer | Outperform → Perform | — |
| 2026-04-14 | main | JP Morgan | Overweight → Overweight | $45 |
| 2026-03-31 | down | Truist Securities | Buy → Hold | $53 |
| 2026-03-30 | down | Barclays | Overweight → Equal-Weight | $53 |
| 2026-03-26 | down | Citizens | Market Outperform → Market Perform | — |
| 2026-03-26 | down | TD Cowen | Buy → Hold | $53 |
| 2026-03-25 | down | HC Wainwright & Co. | Buy → Neutral | $53 |
| 2025-12-11 | main | Citizens | Market Outperform → Market Outperform | $57 |
| 2025-12-09 | main | Truist Securities | Buy → Buy | $56 |
| 2025-12-09 | main | Oppenheimer | Outperform → Outperform | $58 |
| 2025-12-09 | main | BMO Capital | Outperform → Outperform | $54 |
| 2025-12-09 | main | Barclays | Overweight → Overweight | $56 |
| 2025-12-09 | main | Mizuho | Outperform → Outperform | $54 |
| 2025-12-09 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-11-26 | main | Citizens | Market Outperform → Market Outperform | $35 |
| 2025-11-25 | main | Barclays | Overweight → Overweight | $36 |
| 2025-11-19 | main | Truist Securities | Buy → Buy | $35 |
| 2025-11-18 | main | BMO Capital | Outperform → Outperform | $30 |
| 2025-11-13 | main | Mizuho | Outperform → Outperform | $33 |
| 2025-11-11 | main | Barclays | Overweight → Overweight | $28 |
- Why Terns Pharmaceuticals Stock Rocked the Market in March - The Motley Fool Wed, 08 Apr 2026 07
- TERN Stock Price and Chart — LSE:TERN - TradingView ue, 02 Jun 2026 07
- Assessing Terns Pharmaceuticals (TERN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance hu, 02 Apr 2026 07
- Merck’s deal for Terns sparks debate over a possible biotech bidding war - BioPharma Dive hu, 26 Mar 2026 07
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline - CNBC Wed, 25 Mar 2026 07
- Terns Pharmaceuticals (TERN) director options cashed out in $53 Merck deal - Stock Titan ue, 05 May 2026 07
- Terns Pharmaceuticals (TERN) Is Up 8.6% After Pipeline Update And Index Inclusion News - simplywall.st Sun, 15 Mar 2026 07
- Fund Update: New $136.5M $TERN stock position opened by JANUS HENDERSON GROUP PLC - Quiver Quantitative ue, 17 Feb 2026 08
- TERNS PHARMACEUTICALS INC (TERN) Stock Chart - ChartMill Mon, 04 May 2026 07
- Terns rebuffed a higher bid before selling to Merck - BioPharma Dive ue, 07 Apr 2026 07
- Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data - Yahoo Finance Wed, 10 Dec 2025 08
- Merck buys Terns Pharmaceuticals (NASDAQ: TERN) for $53.00 per share in cash - Stock Titan ue, 05 May 2026 07
- As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? - The Motley Fool Mon, 23 Mar 2026 07
- A Look At Terns Pharmaceuticals (TERN) Valuation After Leerink Highlights Early TERN-701 CML Data - Yahoo Finance Sun, 01 Mar 2026 08
- This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally - The Motley Fool Mon, 16 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
110.12
+8.10%
|
101.87
-0.67%
|
102.56
+65.34%
|
62.03
|
| Research And Development |
|
77.89
+11.09%
|
70.11
+10.42%
|
63.50
+60.28%
|
39.62
|
| Selling General And Administration |
|
32.23
+1.50%
|
31.76
-18.69%
|
39.06
+74.29%
|
22.41
|
| General And Administrative Expense |
|
32.23
+1.50%
|
31.76
-18.69%
|
39.06
+74.29%
|
22.41
|
| Other Gand A |
|
32.23
+1.50%
|
31.76
-18.69%
|
39.06
+74.29%
|
22.41
|
| Total Expenses |
|
110.12
+8.10%
|
101.87
-0.67%
|
102.56
+65.34%
|
62.03
|
| Operating Income |
|
-110.12
-8.10%
|
-101.87
+0.67%
|
-102.56
-65.34%
|
-62.03
|
| Total Operating Income As Reported |
|
-110.12
-8.10%
|
-101.87
+0.67%
|
-102.56
-65.34%
|
-62.03
|
| EBITDA |
|
-109.62
-8.56%
|
-100.97
+0.69%
|
-101.68
-66.69%
|
-61.00
|
| Normalized EBITDA |
|
-109.62
-8.56%
|
-100.97
+0.69%
|
-101.68
-66.69%
|
-61.00
|
| Reconciled Depreciation |
|
0.50
-44.08%
|
0.90
+1.70%
|
0.88
-14.63%
|
1.03
|
| EBIT |
|
-110.12
-8.10%
|
-101.87
+0.67%
|
-102.56
-65.34%
|
-62.03
|
| Net Income |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Pretax Income |
|
-95.63
-7.94%
|
-88.59
+1.53%
|
-89.97
-49.98%
|
-59.99
|
| Net Non Operating Interest Income Expense |
|
14.59
+9.80%
|
13.29
+3.01%
|
12.90
+511.42%
|
2.11
|
| Net Interest Income |
|
14.59
+9.80%
|
13.29
+3.01%
|
12.90
+511.42%
|
2.11
|
| Interest Income Non Operating |
|
14.59
+9.80%
|
13.29
+3.01%
|
12.90
+511.42%
|
2.11
|
| Interest Income |
|
14.59
+9.80%
|
13.29
+3.01%
|
12.90
+511.42%
|
2.11
|
| Other Income Expense |
|
-0.09
-745.45%
|
-0.01
+96.50%
|
-0.31
-361.76%
|
-0.07
|
| Other Non Operating Income Expenses |
|
-0.09
-745.45%
|
-0.01
+96.50%
|
-0.31
-361.76%
|
-0.07
|
| Tax Provision |
|
0.58
+123.46%
|
0.26
+8.79%
|
0.24
-33.24%
|
0.36
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Net Income From Continuing Operation Net Minority Interest |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Net Income From Continuing And Discontinued Operation |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Net Income Continuous Operations |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Minority Interests |
|
—
|
—
|
—
|
—
|
| Normalized Income |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Net Income Common Stockholders |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
—
|
-1.12
+11.81%
|
-1.27
+23.95%
|
-1.67
|
| Basic EPS |
|
—
|
-1.12
+11.81%
|
-1.27
+23.95%
|
-1.67
|
| Basic Average Shares |
|
—
|
79.51
+11.57%
|
71.26
+97.76%
|
36.03
|
| Diluted Average Shares |
|
—
|
79.51
+11.57%
|
71.26
+97.76%
|
36.03
|
| Diluted NI Availto Com Stockholders |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,025.08
+181.67%
|
363.93
+35.53%
|
268.52
-6.45%
|
287.03
|
| Current Assets |
|
1,024.19
+182.84%
|
362.11
+35.40%
|
267.43
-6.23%
|
285.19
|
| Cash Cash Equivalents And Short Term Investments |
|
1,018.98
+184.50%
|
358.16
+35.96%
|
263.44
-6.95%
|
283.11
|
| Cash And Cash Equivalents |
|
524.75
+225.04%
|
161.44
+101.99%
|
79.93
-44.20%
|
143.24
|
| Cash Equivalents |
|
500.79
+239.37%
|
147.57
+336.74%
|
33.79
+46.72%
|
23.03
|
| Cash Financial |
|
23.96
+72.70%
|
13.87
-69.93%
|
46.14
-61.62%
|
120.21
|
| Other Short Term Investments |
|
494.24
+151.23%
|
196.72
+7.20%
|
183.51
+31.19%
|
139.88
|
| Receivables |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Current Deferred Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
5.21
+32.12%
|
3.94
-1.18%
|
3.99
+92.76%
|
2.07
|
| Total Non Current Assets |
|
0.88
-51.43%
|
1.82
+67.74%
|
1.08
-41.06%
|
1.84
|
| Net PPE |
|
0.88
-39.86%
|
1.47
+42.86%
|
1.03
-42.96%
|
1.80
|
| Gross PPE |
|
1.57
-53.42%
|
3.36
+27.45%
|
2.64
-17.72%
|
3.21
|
| Accumulated Depreciation |
|
-0.68
+63.95%
|
-1.89
-17.59%
|
-1.61
-14.76%
|
-1.40
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.84
-32.93%
|
1.25
+138.62%
|
0.52
-50.05%
|
1.05
|
| Machinery Furniture Equipment |
|
0.55
-11.18%
|
0.62
+0.98%
|
0.61
-4.98%
|
0.64
|
| Other Properties |
|
—
|
0.75
-2.99%
|
0.77
+1.58%
|
0.76
|
| Leases |
|
0.18
-75.87%
|
0.75
+2.18%
|
0.73
-3.17%
|
0.76
|
| Other Non Current Assets |
|
—
|
0.35
+525.00%
|
0.06
+51.35%
|
0.04
|
| Total Liabilities Net Minority Interest |
|
18.55
+2.74%
|
18.06
+37.33%
|
13.15
+30.42%
|
10.08
|
| Current Liabilities |
|
16.41
+4.86%
|
15.65
+31.03%
|
11.94
+41.05%
|
8.47
|
| Payables And Accrued Expenses |
|
8.57
+25.03%
|
6.86
+27.42%
|
5.38
+42.37%
|
3.78
|
| Payables |
|
1.72
-19.88%
|
2.15
-14.59%
|
2.52
+52.89%
|
1.65
|
| Accounts Payable |
|
1.72
-19.88%
|
2.15
-14.59%
|
2.52
+52.89%
|
1.65
|
| Current Accrued Expenses |
|
6.85
+45.53%
|
4.71
+64.29%
|
2.87
+34.25%
|
2.13
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
6.92
-12.58%
|
7.91
+39.22%
|
5.68
+47.88%
|
3.84
|
| Current Debt And Capital Lease Obligation |
|
0.47
+10.75%
|
0.43
-29.02%
|
0.60
-8.77%
|
0.66
|
| Current Capital Lease Obligation |
|
0.47
+10.75%
|
0.43
-29.02%
|
0.60
-8.77%
|
0.66
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
0.45
-1.32%
|
0.46
+63.67%
|
0.28
+50.27%
|
0.18
|
| Total Non Current Liabilities Net Minority Interest |
|
2.14
-11.04%
|
2.41
+99.75%
|
1.21
-25.33%
|
1.61
|
| Long Term Debt And Capital Lease Obligation |
|
0.45
-51.58%
|
0.92
|
0.00
-100.00%
|
0.54
|
| Long Term Capital Lease Obligation |
|
0.45
-51.58%
|
0.92
|
0.00
-100.00%
|
0.54
|
| Tradeand Other Payables Non Current |
|
1.70
+13.96%
|
1.49
+23.55%
|
1.21
+12.61%
|
1.07
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Common Stock Equity |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Capital Stock |
|
0.01
+22.22%
|
0.01
+50.00%
|
0.01
+20.00%
|
0.01
|
| Common Stock |
|
0.01
+22.22%
|
0.01
+50.00%
|
0.01
+20.00%
|
0.01
|
| Preferred Stock |
|
—
|
—
|
—
|
—
|
| Share Issued |
|
112.32
+28.92%
|
87.13
+34.92%
|
64.58
+20.20%
|
53.72
|
| Ordinary Shares Number |
|
112.32
+28.92%
|
87.13
+34.92%
|
64.58
+20.20%
|
53.72
|
| Additional Paid In Capital |
|
1,523.94
+98.53%
|
767.62
+30.55%
|
588.01
+13.04%
|
520.18
|
| Retained Earnings |
|
-517.69
-22.83%
|
-421.48
-26.71%
|
-332.63
-37.21%
|
-242.42
|
| Gains Losses Not Affecting Retained Earnings |
|
0.26
+193.19%
|
-0.28
-1368.42%
|
-0.02
+97.69%
|
-0.82
|
| Other Equity Adjustments |
|
0.26
+193.19%
|
-0.28
-1368.42%
|
-0.02
+97.69%
|
-0.82
|
| Total Equity Gross Minority Interest |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Total Capitalization |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Working Capital |
|
1,007.78
+190.88%
|
346.46
+35.61%
|
255.49
-7.67%
|
276.72
|
| Invested Capital |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Total Debt |
|
0.92
-31.77%
|
1.35
+123.38%
|
0.60
-49.96%
|
1.21
|
| Capital Lease Obligations |
|
0.92
-31.77%
|
1.35
+123.38%
|
0.60
-49.96%
|
1.21
|
| Net Tangible Assets |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Tangible Book Value |
|
1,006.52
+191.01%
|
345.87
+35.44%
|
255.37
-7.79%
|
276.94
|
| Notes Receivable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-82.18
-17.37%
|
-70.02
-3.90%
|
-67.39
-37.23%
|
-49.11
|
| Cash Flow From Continuing Operating Activities |
|
-82.18
-17.37%
|
-70.02
-3.90%
|
-67.39
-37.23%
|
-49.11
|
| Net Income From Continuing Operations |
|
-96.21
-8.28%
|
-88.85
+1.50%
|
-90.21
-49.49%
|
-60.34
|
| Depreciation Amortization Depletion |
|
0.50
-44.08%
|
0.90
+1.70%
|
0.88
-14.63%
|
1.03
|
| Depreciation |
|
0.50
-44.08%
|
0.90
+1.70%
|
0.88
-14.63%
|
1.03
|
| Depreciation And Amortization |
|
0.50
-44.08%
|
0.90
+1.70%
|
0.88
-14.63%
|
1.03
|
| Stock Based Compensation |
|
13.40
-14.26%
|
15.63
-38.80%
|
25.54
+137.15%
|
10.77
|
| Deferred Tax |
|
0.51
+2121.74%
|
0.02
-83.69%
|
0.14
-64.03%
|
0.39
|
| Deferred Income Tax |
|
0.51
+2121.74%
|
0.02
-83.69%
|
0.14
-64.03%
|
0.39
|
| Change In Working Capital |
|
-0.32
-107.33%
|
4.38
+197.02%
|
1.48
+242.24%
|
-1.04
|
| Change In Prepaid Assets |
|
-1.18
-2612.77%
|
0.05
+102.45%
|
-1.92
-71.36%
|
-1.12
|
| Change In Payables And Accrued Expense |
|
1.29
-73.61%
|
4.89
+20.36%
|
4.06
+485.30%
|
0.69
|
| Change In Accrued Expense |
|
1.80
-65.72%
|
5.26
+80.43%
|
2.91
+105.72%
|
1.42
|
| Change In Payable |
|
-0.51
-39.51%
|
-0.37
-131.94%
|
1.15
+259.14%
|
-0.72
|
| Change In Account Payable |
|
-0.51
-39.51%
|
-0.37
-131.94%
|
1.15
+259.14%
|
-0.72
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.61
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
0.00
|
| Change In Other Current Liabilities |
|
-0.43
+22.52%
|
-0.56
+16.67%
|
-0.67
-9.18%
|
-0.61
|
| Investing Cash Flow |
|
-298.04
-2301.64%
|
-12.41
+67.33%
|
-37.99
-70.56%
|
-22.27
|
| Cash Flow From Continuing Investing Activities |
|
-298.04
-2301.64%
|
-12.41
+67.33%
|
-37.99
-70.56%
|
-22.27
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.04
+19.23%
|
-0.05
+81.09%
|
-0.28
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.04
+19.23%
|
-0.05
+81.09%
|
-0.28
|
| Capital Expenditure |
|
—
|
-0.04
+19.23%
|
-0.05
+81.09%
|
-0.28
|
| Net Investment Purchase And Sale |
|
-298.04
-2309.79%
|
-12.37
+67.40%
|
-37.94
-72.46%
|
-22.00
|
| Purchase Of Investment |
|
-405.04
-138.34%
|
-169.94
+38.38%
|
-275.78
-97.37%
|
-139.73
|
| Sale Of Investment |
|
107.00
-32.10%
|
157.57
-33.75%
|
237.85
+102.02%
|
117.73
|
| Financing Cash Flow |
|
743.51
+353.37%
|
164.00
+290.92%
|
41.95
-74.89%
|
167.09
|
| Cash Flow From Continuing Financing Activities |
|
743.51
+353.37%
|
164.00
+290.92%
|
41.95
-74.89%
|
167.09
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
706.39
+335.20%
|
162.31
+290.07%
|
41.61
-75.12%
|
167.25
|
| Proceeds From Stock Option Exercised |
|
37.36
+1703.86%
|
2.07
+202.78%
|
0.68
+181.48%
|
0.24
|
| Net Other Financing Charges |
|
-0.23
+39.43%
|
-0.39
-12.79%
|
-0.34
+14.21%
|
-0.40
|
| Changes In Cash |
|
363.29
+345.38%
|
81.57
+228.60%
|
-63.43
-166.27%
|
95.71
|
| Effect Of Exchange Rate Changes |
|
0.02
+128.57%
|
-0.06
-147.86%
|
0.12
+165.73%
|
-0.18
|
| Beginning Cash Position |
|
161.44
+101.99%
|
79.93
-44.20%
|
143.24
+200.29%
|
47.70
|
| End Cash Position |
|
524.75
+225.04%
|
161.44
+101.99%
|
79.93
-44.20%
|
143.24
|
| Free Cash Flow |
|
-82.18
-17.30%
|
-70.06
-3.88%
|
-67.44
-36.57%
|
-49.38
|
| Income Tax Paid Supplemental Data |
|
0.22
+263.33%
|
0.06
+114.29%
|
0.03
+833.33%
|
0.00
|
| Amortization Of Securities |
|
-0.06
+97.22%
|
-2.09
+59.91%
|
-5.21
-6535.80%
|
0.08
|
| Change In Interest Payable |
|
1.17
+15.91%
|
1.01
+450.00%
|
0.18
|
—
|
| Common Stock Issuance |
|
706.39
+335.20%
|
162.31
+290.07%
|
41.61
-75.12%
|
167.25
|
| Issuance Of Capital Stock |
|
706.39
+335.20%
|
162.31
+290.07%
|
41.61
-75.12%
|
167.25
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|